Aeglea Bio Therapeutics Inc (NASDAQ:AGLE)

0.52
BATS BZX Real-Time Price
As of 9:39am ET
 +0.009 / +1.76%
Today’s Change
0.50
Today|||52-Week Range
8.50
-89.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$31.2M

Company Description

Aeglea Biotherapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Contact Information

Aeglea Biotherapeutics, Inc.
805 Las Cimas Parkway
Austin Texas 78746
P:(512) 942-2935
Investor Relations:

Employees

Shareholders

Other institutional42.26%
Individual stakeholders19.02%
Mutual fund holders16.14%

Top Executives

Anthony G. QuinnPresident, Chief Executive Officer & Director
Leslie SloanChief Operating Officer
Jonathan D. AlspaughChief Financial & Accounting Officer
Scott W. RowlinsonVice President-Research
Cortney CaudillSenior Vice President-Technical Operations